KLRK1 and glioblastoma: In vitro experiments in U-251 MG, T98G, U-87 MG, and HTB185 glioblastoma cell lines showed that NKG2D CAR-T cells effectively targeted cancer stem cells, as confirmed by the elevated production of NKG2D ligands [112].